Core evidence outcomes summary for ustekinumab in psoriasis

Outcome measure	Evidence	Implications
Disease-oriented evidence
Statistically significant PASI 75 responses	Clear	Ustekinumab effectively controls psoriasis and improves clearance rates compared to placebo
Time to relapse	Substantial	The median time to loss of PASI 75 after withdrawal was about 15 weeks
Patient-oriented evidence
Quality of life improvement	Clear	Ustekinumab considerably improves quality of life in psoriatic patients compared to placebo
Tolerability	Moderate	Safety profile similar to other biologics Further studies are required to evaluate long-term tolerability
Economic evidence
Cost effectiveness	No evidence

Abbreviations: PASI, Psoriasis Area and Severity Index.